Clinical Trial Update: A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating ABT-263 as a single agent in women with platinum-resistant or refractory recurrent ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• ABT-263 (navitoclax)

Snippet

Sponsor: Centre Francois Baclesse | Conditions: Platinum-resistant or Refractory Ovarian Cancer | Phase 2 | Status: COMPLETED